3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of 3-AP in treating patients
with advanced or metastatic solid tumors. 3-AP may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth.